‘Jardiance’ challenges first cardiovascular disease prevention as antidiabetic
‘Jardiance’ challenges to secure the ‘cardiovascular disease prevention’ indication for the first time as a diabetes drug.
According to the industry concerned on the 27th, Boehringer Ingelheim and Lilly turned in application of indication extension over cardiovascular risk reduction to the Minis...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
